|
dnaJ Peptide for Relieving Rheumatoid Arthritis Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about dnaJ Peptide for Relieving Rheumatoid Arthritis conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. dnaJ Peptide for Relieving Rheumatoid Arthritis Clinical research trials and dnaJ Peptide for Relieving Rheumatoid Arthritis health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including dnaJ Peptide for Relieving Rheumatoid Arthritis. dnaJ Peptide for Relieving Rheumatoid Arthritis Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a dnaJ Peptide for Relieving Rheumatoid Arthritis clinical trial. Test subjects typically receive the most expert healthcare available for their dnaJ Peptide for Relieving Rheumatoid Arthritis condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > dnaJ Peptide for Relieving Rheumatoid Arthritis  dnaJ Peptide for Relieving Rheumatoid Arthritis
dnaJ Peptide for Relieving Rheumatoid Arthritis
For Condition: Rheumatoid Arthritis
Status: Recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: A small protein called dnaJ peptide may help people with rheumatoid arthritis (RA) by preventing their immune system cells from attacking their own tissues. The purpose of this study is to determine if small amounts of dnaJ peptide can "re-educate" immune cells in people with RA so that the cells stop attacking joint tissues.
Details: Immune modulation is a promising new approach for the treatment of RA. Studies have shown that immune cells in the joints of people in the early stages of RA react strongly against dnaJ peptides from bacteria. These immune cells may also cross-react with human dnaJ peptides in the joints to cause inflammation. dnaJ may help RA by "re-educating" the immune system and dampening the abnormal inflammatory immune response in RA. This study will last 7 months. Participants will be randomly assigned to receive either dnaJ or placebo by mouth. At screening, participants will have medical history, physical, and medication assessment. At screening, at 6 study visits every month after the start of treatment, and at 1 month follow-up, participants will have a joint exam, blood and urine collection, and will fill out a questionnaire about their condition.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/85 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Active rheumatoid arthritis as defined by the revised American College of Rheumatology (ACR) 1987 criteria. Evidence of active disease will be based on at least six swollen or nine tender joints. - Diagnosis of rheumatoid arthritis of less than 5 years - Reactivity to dnaJ - Agree to use acceptable methods of contraception - Able to understand and sign informed consent Exclusion Criteria: - Patients taking more 7.5 mg of prednisone or disease modifying agents other than hydrochloroquine or sulfasalazine (i.e., gold, penicillamine, azathioprine, cyclophosphamide, methotrexate, cyclosporine or anti-TNF agents) - Serum creatinine greater than 1.5 mg/dl - SGOT less than SGPT - Alkaline phosphatase greater than 2x age/sex adjusted normal values - Hematocrit of less than 30 - Platelets less than 130,000 - History of lymphoma - Any active malignancy or cancer requiring treatment in the last 5 years, except for nonmelanoma skin cancers and carcinoma of the cervix in situ - Medical or psychiatric condition or active serious infection - Pregnant or breastfeeding
Total Enrollment: 160
Location and Contact Information:
Overall Study Official:
SalvatoreAlbani, Principal Investigator, University of California, San Diego
Johns Hopkins University *Recruiting*
Baltimore, Maryland, 21224
United States
Recruiting Marilyn Towns 410-550-0579
University of California, Irvine Medical Center *Not yet recruiting*
Orange, California, 92868
United States
Not yet recruiting Irvine Center Trial Recruiter 714-456-7647
Mayo Clinic *Recruiting*
Rochester, Minnesota, 55905
United States
Recruiting Jane Jaquith 507-284-4502
Guthrie Clinic *Recruiting*
Sayre, Pennsylvania, 18840
United States
Recruiting Karen Zombolas 570-882-6092
Stanford University *Recruiting*
Palo Alto, California, 94305
United States
Recruiting Cheryl Kallmann 650-723-8516
University of Arizona Health Sciences Center *Recruiting*
Tucson, Arizona, 85724-5093
United States
Recruiting Jo McClain 520-694-2319
Denver Arthritis Center *Not yet recruiting*
Denver, Colorado, 80230
United States
Not yet recruiting Janet Bird 303-394-2828
Virginia Mason Research Center *Recruiting*
Seattle, Washington, 98104
United States
Recruiting Carey Edwards 206-223-6836
Additional Information:
Study ID Numbers: NIAMS-042; N01-AR-9-2241
Study Start Date: September 1999
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000435
Other Rheumatoid Arthritis Studies:
1. Safety and efficacy of a monoclonal antibody for treatment of rheumatoid arthritis.
2. Identification of Genes Associated with Lung Disease in Patients with Rheumatoid Arthritis
3. Genetic Registry for Rheumatoid Arthritis
4. Literacy in Arthritis Management
5. Long term safety and tolerability of an investigational drug in patients with rheumatoid arthritis
Related Studies:
Other Rheumatoid Arthritis Clinical Trials
Other Washington Clinical Trials
Other Seattle Clinical Trials
dnaJ Peptide for Relieving Rheumatoid Arthritis
|
|
|
|
|
|
|
|
